Terbinafine CAS: 91161-71-6

CAS NO: 91161-71-6
Terbinafine
Chemical Name: Terbinafine
Molecular Formula: C21H25N
Formula Weight: 291.43
CAS No.: 91161-71-6
Description Review
Description

Terbinafine is an antifungal medication used to treat a variety of fungal infections, including athlete's foot, ringworm, and onychomycosis. It is marketed under the trade name Lamisil and is available in oral and topical forms. In this article, we will provide an overview of Terbinafine, its chemical properties, health benefits, potential effects, mechanism of action, safety, side effects, and dosing information.

Introducing Terbinafine:

Terbinafine is a synthetic allylamine derivative that was first introduced in the mid-1990s. It is used to treat various fungal infections of the skin, hair, and nails. The medication works by interfering with the production of ergosterol, which is a component of fungal cell membranes essential for their growth.

Chemical Properties:

The chemical name of Terbinafine is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine. Its molecular formula is C21H26N, and its formula weight is 291.44 g/mol. Its CAS number is 91161-71-6.

Top Ten Keywords and Synonyms:

  1. Terbinafine mechanism of action
  2. Antifungal medication
  3. Lamisil
  4. Fungal infections
  5. Onychomycosis
  6. Athlete's foot
  7. Jock itch
  8. Ringworm
  9. Topical cream
  10. Oral tablets

Health Benefits:

Terbinafine has demonstrated significant health benefits in the treatment of fungal infections of the skin, hair, and nails. It can effectively treat conditions such as athlete's foot, jock itch, ringworm, and onychomycosis. By eliminating the fungus causing the infection, Terbinafine can relieve symptoms such as itching, scaling, and inflammation.

Potential Effects:

Terbinafine has shown promising potential in preclinical studies and clinical trials. In addition to its effectiveness in treating fungal infections of the skin, it may also have activity against other types of fungi, such as Aspergillus and Candida species. Furthermore, it may have potential for use in combination therapy with other medications or as a prophylactic agent in high-risk patients.

Product Mechanism:

Terbinafine works by inhibiting the activity of squalene epoxidase, an enzyme involved in the synthesis of ergosterol in fungal cell membranes. By blocking the production of ergosterol, Terbinafine disrupts the structure and function of fungal cell membranes, leading to the death of the fungus causing the infection.

Safety:

Terbinafine has been shown to be generally safe and well-tolerated in clinical trials. However, like any medication, it may cause side effects, which are discussed below.

Side Effects:

The most commonly reported side effects of Terbinafine include gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain. Other potential side effects may include liver dysfunction, skin rashes, and allergic reactions. Rarely, serious adverse events such as Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported in association with Terbinafine.

Dosing Information:

The optimal dosing regimen for Terbinafine varies depending on the type and severity of the fungal infection being treated. Typically, for onychomycosis, adults take 250 mg orally daily for 6 to 12 weeks. For other types of fungal infections, topical creams or ointments may be used. Dose adjustments may be necessary based on individual response and tolerability.

Conclusion:

Terbinafine is an effective antifungal medication used to treat fungal infections of the skin, hair, and nails. By inhibiting the activity of squalene epoxidase, Terbinafine disrupts the structure and function of fungal cell membranes, leading to the death of the fungus causing the infection. While Terbinafine has been generally well-tolerated in clinical trials, it may cause side effects, and patients should be closely monitored while taking this medication. Overall, Terbinafine represents an important tool in the treatment of fungal infections and highlights the importance of effective antifungal therapy for improved patient outcomes

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code